Passage Bio Added to Russell 2000 Index
June 26 2020 - 8:00AM
Passage Bio, Inc. (NASDAQ: PASG), a genetic medicines company
focused on developing transformative therapies for rare, monogenic
central nervous system disorders, today announced that it has been
added to the Russell 2000® Index, effective as of market close
today.
The Russell 2000® Index measures the performance of the
small-cap segment of the U.S. equity market. The index is a subset
of the Russell 3000® Index and represents approximately 10 percent
of the total market capitalization of that index. Russell indexes
are widely used by investment managers and institutional investors
for index funds and as benchmarks for active investment strategies.
Approximately $9 trillion in assets are benchmarked against
Russell’s U.S. indexes. Russell indexes are part of FTSE Russell, a
leading global index provider.
About Passage Bio Passage Bio is a genetic
medicines company focused on developing transformative therapies
for rare, monogenic central nervous system disorders with limited
or no approved treatment options. The company is based in
Philadelphia, PA and has a research, collaboration and license
agreement with the University of Pennsylvania and its Gene Therapy
Program (GTP). The GTP conducts discovery and IND-enabling
preclinical work and Passage Bio conducts all clinical development,
regulatory strategy and commercialization activities under the
agreement. The company has a development portfolio of six product
candidates, with the option to license eleven more, with lead
programs in GM1 gangliosidosis, frontotemporal dementia and Krabbe
disease.
For further information, please contact:
Investors:Sarah McCabeStern Investor Relations,
Inc.212-362-1200sarah.mccabe@sternir.com
Media:Azeem ZeekryaHDMZ312-506-5244azeem.zeekrya@hdmz.com
Passage Bio (NASDAQ:PASG)
Historical Stock Chart
From Jun 2024 to Jul 2024
Passage Bio (NASDAQ:PASG)
Historical Stock Chart
From Jul 2023 to Jul 2024